Translation for cancer therapeutics is taking too long and costing too much, according to Dr. Philip Schein, visiting professor in cancer pharmacology at the University of Oxford in England and leading international authority in the treatment of cancer. How can we improve in the future? Join host Dr. Bruce Bloom's conversation with Dr. Schein and Scott Riccio, founder and director for Accelerate Progress, a not-for-profit "action-tank" focused on bringing new promising and potentially lifesaving therapies to cancer patients, about why and how we should truncate the lengthy approval process and decrease the costs of bringing new therapeutics to market.
Speeding Up Translation of New Cancer Therapeutics
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Translation for cancer therapeutics is taking too long and costing too much, according to Dr. Philip Schein, visiting professor in cancer pharmacology at the University of Oxford in England and leading international authority in the treatment of cancer. How can we improve in the future? Join host Dr. Bruce Bloom's conversation with Dr. Schein and Scott Riccio, founder and director for Accelerate Progress, a not-for-profit "action-tank" focused on bringing new promising and potentially lifesaving therapies to cancer patients, about why and how we should truncate the lengthy approval process and decrease the costs of bringing new therapeutics to market.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Updates From the 7th World Symposium Task Force
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
Pulmonary Hypertension Management: Practice Trends and Updates
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?